Healthcare provider profile · identity verified

Thomas James Westwick, M.D.

Internal Medicine · TEMPLE, TX · NPI 1689636508

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	672	202
Rosuvastatin Calcium	Rosuvastatin Calcium	522	156
Levothyroxine Sodium	Levothyroxine Sodium	442	115
Amlodipine Besylate	Amlodipine Besylate	433	129
Losartan Potassium	Losartan Potassium	384	121
Lisinopril	Lisinopril	383	110
Gabapentin	Gabapentin	330	105
Metoprolol Succinate	Metoprolol Succinate	244	68
Omeprazole	Omeprazole	242	74
Metformin Hcl	Metformin Hcl	215	65
Tamsulosin Hcl	Tamsulosin Hcl	188	55
Eliquis	Apixaban	187	56
Metoprolol Tartrate	Metoprolol Tartrate	135	42
Sertraline Hcl	Sertraline Hcl	131	40
Fluticasone Propionate	Fluticasone Propionate	118	44
Pantoprazole Sodium	Pantoprazole Sodium	117	45
Hydrochlorothiazide	Hydrochlorothiazide	116	38
Furosemide	Furosemide	113	41
Jardiance	Empagliflozin	110	33
Metformin Hcl Er	Metformin Hcl	107	34
Simvastatin	Simvastatin	103	32
Carvedilol	Carvedilol	102	38
Albuterol Sulfate Hfa	Albuterol Sulfate	101	40
Spironolactone	Spironolactone	97	37
Tizanidine Hcl	Tizanidine Hcl	97	27
Ozempic	Semaglutide	93	19
Potassium Chloride	Potassium Chloride	87	27
Allopurinol	Allopurinol	86	23
Duloxetine Hcl	Duloxetine Hcl	86	29
Ezetimibe	Ezetimibe	81	34
Famotidine	Famotidine	71	23
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	70	20
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	69	24
Tramadol Hcl	Tramadol Hcl	69	19
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	67	67
Finasteride	Finasteride	66	19
Trazodone Hcl	Trazodone Hcl	62	17
Pravastatin Sodium	Pravastatin Sodium	58	19
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	56	17
Glimepiride	Glimepiride	54	18
Mirtazapine	Mirtazapine	53	17
Clopidogrel	Clopidogrel Bisulfate	50	13
Pioglitazone Hcl	Pioglitazone Hcl	49	15
Buspirone Hcl	Buspirone Hcl	48	19
Triamcinolone Acetonide	Triamcinolone Acetonide	47	25
Montelukast Sodium	Montelukast Sodium	44	13
Clonazepam	Clonazepam	43	suppressed
Alendronate Sodium	Alendronate Sodium	42	16
Valsartan	Valsartan	42	13
Nitroglycerin	Nitroglycerin	40	22
Pregabalin	Pregabalin	39	11
Synthroid	Levothyroxine Sodium	39	suppressed
Atenolol	Atenolol	38	11
Flecainide Acetate	Flecainide Acetate	37	12
Mounjaro	Tirzepatide	37	suppressed
Rybelsus	Semaglutide	37	suppressed
Glipizide	Glipizide	36	11
Donepezil Hcl	Donepezil Hcl	33	11
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	33	31
Amiodarone Hcl	Amiodarone Hcl	32	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	32	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	31	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	29	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	28	suppressed
Terazosin Hcl	Terazosin Hcl	28	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	26	11
Alprazolam	Alprazolam	25	suppressed
Celecoxib	Celecoxib	25	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	25	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	25	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	24	suppressed
Hydralazine Hcl	Hydralazine Hcl	24	suppressed
Levetiracetam	Levetiracetam	24	suppressed
Ketoconazole	Ketoconazole	23	suppressed
Meloxicam	Meloxicam	23	suppressed
Ventolin Hfa	Albuterol Sulfate	23	suppressed
Acyclovir	Acyclovir	22	suppressed
Myrbetriq	Mirabegron	22	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	22	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	21	suppressed
Divalproex Sodium	Divalproex Sodium	21	suppressed
Entresto	Sacubitril/Valsartan	21	suppressed
Ibuprofen	Ibuprofen	21	suppressed
Paroxetine Hcl	Paroxetine Hcl	21	suppressed
Prednisone	Prednisone	21	16
Valacyclovir	Valacyclovir Hcl	21	13
Xarelto	Rivaroxaban	21	suppressed
Bupropion Hcl Sr	Bupropion Hcl	20	suppressed
Ondansetron Odt	Ondansetron	20	suppressed
Latanoprost	Latanoprost	19	suppressed
Clotrimazole	Clotrimazole	18	suppressed
Estradiol	Estradiol	18	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	18	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	18	suppressed
Lorazepam	Lorazepam	17	suppressed
Hydrocortisone	Hydrocortisone	16	suppressed
Ipratropium Bromide	Ipratropium Bromide	16	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	16	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	16	suppressed
Azelastine Hcl	Azelastine Hcl	15	suppressed
Boostrix Tdap	Diphth,pertuss(Acell),tet Vac	15	15
Spironolactone-Hctz	Spironolact/Hydrochlorothiazid	15	suppressed
Alfuzosin Hcl Er	Alfuzosin Hcl	14	suppressed
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	14	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	14	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	14	suppressed
Meclizine Hcl	Meclizine Hcl	14	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	14	suppressed
Trulicity	Dulaglutide	14	suppressed
Cefuroxime	Cefuroxime Axetil	13	12
Humalog Kwikpen U-100	Insulin Lispro	13	suppressed
Ibu	Ibuprofen	12	suppressed
Symbicort	Budesonide/Formoterol Fumarate	12	suppressed
Verapamil Er	Verapamil Hcl	12	suppressed
Icosapent Ethyl	Icosapent Ethyl	11	suppressed
Ondansetron Hcl	Ondansetron Hcl	11	suppressed
Ropinirole Hcl	Ropinirole Hcl	11	suppressed
Solifenacin Succinate	Solifenacin Succinate	11	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error